ArticleAACE endocrinology and diabetes
Thyrotropin (TSH)-Binding Inhibiting Immunoglobulin-Negative, Thyroid-Stimulating Antibody-Positive Amiodarone-Induced Thyrotoxicosis.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Amiodarone-induced thyrotoxicosis (AIT) is classified into type 1 (AIT1) and type 2 (AIT2) using several diagnostic procedures, including thyrotropin receptor antibodies (TRAbs). While thyrotropin-binding inhibiting immunoglobulin (TBII) and thyroid-stimulating antibody (TSAb) are widely used TRAb assays for diagnosing Graves' disease, their roles in distinguishing AIT subtypes remain unclear. Herein, we report a patient with TBII-negative, TSAb-positive AIT1. Case Report: A 32-year-old man with a history of ventricular fibrillation, who had been receiving amiodarone for 4 years, presented with diffuse goiter and palpitations. Endocrinologic evaluation revealed thyrotoxicosis with undetectable TBII levels, measured using an M22 human monoclonal TRAb assay. Although the patient was initially diagnosed with AIT2 and treated with prednisolone, his positive TSAb bioassay results and normal thyroid uptake on technetium-99m pertechnetate scintigraphy suggested AIT1. Prednisolone alone partially reduced thyroid hormone levels, whereas the addition of methimazole normalized thyroid function, indicating AIT1 due to underlying Graves' disease, possibly coexisting with AIT2. Discussion: This case highlights that TBII can be negative in AIT1 and can underscore the potential diagnostic utility of TSAb measurement. These findings suggest that TSAb measurement may serve as supportive evidence for diagnosing AIT1 in TBII-negative patients. Conclusion: We report a case of TBII-negative, TSAb-positive AIT1, highlighting the role of TSAb measurement in detecting AIT1, particularly in TBII-negative AIT patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.